Mount Yale Investment Advisors LLC Purchases 840 Shares of Danaher Co. (NYSE:DHR)

Mount Yale Investment Advisors LLC boosted its position in shares of Danaher Co. (NYSE:DHR) by 84.3% in the first quarter, Holdings Channel.com reports. The institutional investor owned 1,836 shares of the conglomerate’s stock after acquiring an additional 840 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Danaher were worth $459,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in DHR. Cape Investment Advisory Inc. bought a new position in shares of Danaher in the 4th quarter valued at about $25,000. Tsfg LLC raised its position in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the period. Wetzel Investment Advisors Inc. bought a new stake in shares of Danaher in the 4th quarter valued at approximately $29,000. Redmont Wealth Advisors LLC purchased a new position in shares of Danaher in the 1st quarter worth approximately $30,000. Finally, Rakuten Securities Inc. bought a new position in shares of Danaher during the 4th quarter valued at approximately $36,000. Institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on DHR. Barclays raised their price target on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 24th. Evercore ISI lowered their target price on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. The Goldman Sachs Group upped their price target on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Finally, HSBC upgraded Danaher from a “hold” rating to a “buy” rating and boosted their price objective for the company from $250.00 to $280.00 in a report on Wednesday, April 17th. Six investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $276.88.

Danaher Stock Down 0.8 %

Shares of DHR traded down $2.26 during trading hours on Monday, hitting $271.65. The company had a trading volume of 2,139,546 shares, compared to its average volume of 2,916,600. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $196.19 billion, a PE ratio of 46.46, a price-to-earnings-growth ratio of 4.24 and a beta of 0.84. Danaher Co. has a one year low of $182.09 and a one year high of $277.72. The company’s fifty day moving average price is $255.16 and its two-hundred day moving average price is $249.35.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the company posted $2.05 earnings per share. The firm’s revenue was down 2.9% on a year-over-year basis. As a group, equities analysts forecast that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, July 26th. Shareholders of record on Friday, June 28th were issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.40%. The ex-dividend date was Friday, June 28th. Danaher’s dividend payout ratio is currently 18.31%.

Insider Transactions at Danaher

In other news, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the transaction, the director now owns 116,202 shares in the company, valued at $28,304,483.16. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Danaher news, CEO Rainer Blair sold 19,085 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $255.00, for a total value of $4,866,675.00. Following the completion of the transaction, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at $29,578,725. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The disclosure for this sale can be found here. Over the last three months, insiders have sold 84,775 shares of company stock valued at $21,802,690. Corporate insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.